UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca

26 February 2021
UN0421696
UNICEF/UN0421696/Singh (File Photo)
An employee inspects a COVID-19 vaccine vial produced for the COVAX facility at a manufacturer in Pune, a city located in the western Indian state of Maharashtra (24 February 2021)

COPENHAGEN/NEW YORK, 25 February 2021 – UNICEF and AstraZeneca this week signed a long-term agreement for the supply of COVID-19 Vaccine AstraZeneca on behalf of the COVAX Facility.  

Through the supply agreement, UNICEF, along with procurement partners including the Pan-American Health Organization (PAHO), will have access to up to 170 million doses of vaccines for around 85 countries. This is the third such agreement for COVID-19 vaccines, following previously announced agreements with Pfizer and the Serum Institute of India. 

The AstraZeneca/Oxford vaccine received WHO Emergency Use Listing (EUL) on 15 February. 

Deliveries of the vaccine  are planned to begin in the first quarter of 2021, in line with the COVAX Allocation Framework that take into consideration several factors including country readiness, national regulatory authorizations and completed contractual provisions, as well as operating and supply considerations.   

The goal of the COVAX Facility is to ensure that safe, effective COVID-19 vaccines are rapidly available and affordable to all countries around the world, regardless of income level. 

The supply agreement will enable access to 170 million doses secured under the COVAX Facility’s Advance Purchase Agreement (APA) with AstraZeneca, which will be available throughout 2021.  

On 11 February, UNICEF announced the signing of an agreement with Pfizer for the supply of the Pfizer-BioNTech COVID-19 Vaccine through 2021, following on from an agreement with the Serum Institute of India to access two vaccines through technology transfer from AstraZeneca which has been granted WHO EUL  and Novavax, which is subject to the approval of the vaccine by WHO.    

The COVAX Facility, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, together with UNICEF, aims to provide at least 2 billion doses of approved COVID-19 vaccines by the end of 2021, enabling the protection of frontline health care and social workers, as well as other high-risk and vulnerable groups.   

#####   

Notes to editors:  

Sharing pricing information is a reflection to UNICEF’s commitment to transparency, which the organization has been demonstrating for the past ten years by publishing all negotiated prices for a range of commodities. As these supply agreements are concluded, UNICEF will continue to make public relevant details of the agreements, subject to the consent of the suppliers. 

Media contacts

Eliane Luthi
Regional Chief of Communication
UNICEF Regional Office for South Asia
Tel: +977-98010 30076
Anne Sophie Bonefeld
UNICEF Copenhagen
Tel: +4524694676

Additional resources

UN0420498

Additional resources for media

About UNICEF

UNICEF works in some of the world’s toughest places, to reach the world’s most disadvantaged children. Across more than 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. For more information about UNICEF and its work for children, visit www.unicef.org. Follow UNICEF on Twitter and Facebook.  

The UNICEF South Asia region include Afghanistan, Bangladesh, Bhutan, India, the Maldives, Nepal, Pakistan and Sri Lanka.  

UNICEF’s Regional Office for South Asia (ROSA) works with all eight UNICEF Country Offices in South Asia to help to save children’s lives, defend their rights, and help them fulfil their potential. Follow UNICEF ROSA on Twitter and Facebook. For more information about COVID-19, click here.